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Loss of tolerance to gut immunity 
protein, glycoprotein 2 (GP2) 
is associated with progressive 
disease course in primary sclerosing 
cholangitis
Tamas Tornai  1, David Tornai2, Nora Sipeki1, Istvan Tornai1, Rayan Alsulaimani2, Kai 
Fechner3, Dirk Roggenbuck  4,5, Gary L. Norman  6, Gabor Veres7, Gabriella Par8, Alajos Par8, 
Ferenc Szalay9, Peter Laszlo Lakatos9, Peter Antal-Szalmas2 & Maria Papp  1
Glycoprotein 2[GP2] is a specific target of pancreatic autoantibodies[PAbs] in Crohn’s disease(CD) and 
is involved in gut innate immunity processes. Our aim was to evaluate the prevalence and prognostic 
potential of PAbs in primary sclerosing cholangitis(PSC). Sixty-five PSC patients were tested for 
PAbs by indirect immunofluorescence and compared with healthy (n = 100) and chronic liver disease 
controls(CLD, n = 488). Additionally, a panel of anti-microbial antibodies and secretory (s)IgA levels 
were measured, as markers of bacterial translocation and immune dysregulation. PAbs were more 
frequent in PSC(46.2%) compared to controls(healthy:0% and CLD:4.5%), [P < 0.001, for each]. 
Occurrence of anti-GP2 antibody was 30.8% (20/65) and was exclusively of IgA isotype. Anti-GP2 IgA 
positive patients had higher sIgA levels (P = 0.021). With flow-cytometry, 68.4% (13/19) of anti-GP2 
IgA antibodies were bound with secretory component, suggesting an active retro-transportation of 
anti-GP2 from the gut lumen to the mucosa. Anti-GP2 IgA was associated with shorter transplant-
free survival [PLogRank < 0.01] during the prospective follow-up (median, IQR: 87 [9–99] months) 
and remained an independent predictor after adjusting for Mayo risk score(HR: 4.69 [1.05–21.04], 
P = 0.043). These results highlight the significance of gut-liver interactions in PSC. Anti-GP2 IgA might 
be a valuable tool for risk stratification in PSC and considered as a potential therapeutic target.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by persistent, progressive 
biliary inflammation and fibrosis. Clinical manifestations and progression of the disease are heterogeneous and 
lack reliable biomarkers. Consequently, patients with PSC cannot be stratified appropriately1. Until now only a 
clinical score, the Mayo risk score, has been proved useful in risk assessment of the disease2. While the etiology 
of the disease is poorly understood, a dysregulated interplay of key genetic and immunologic pathways with the 
microbiome appears to contribute to the development of PSC and associated inflammatory bowel diseases (IBD)3. 
A more detailed exploration of derangement in gut-liver axis might lead to assist the development of disease 
specific therapy. There is an unmet need for effective medical treatments for PSC, and to date, the only curative 
therapy is liver transplantation reserved for those with end-stage liver disease4.
Enhanced formation of autoantibodies against acinar cells of the exocrine pancreas have long been described 
in Crohn’s disease (CD) and considered one of the various serological hallmarks of the disease5. Recently, 
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the target antigens of pancreatic autoantibodies (PAbs) have been identified: the pancreatic major glycopro-
tein of the zymogen granule membrane (GP2, also referred to as MZGP2) and CUB and zona pellucida-like 
domain-containing protein 1 (CUZD1)6,7. Further investigations revealed that GP2 plays an important role in 
intestinal immune responses8,9. Previously, we demonstrated in a large cohort of patients with IBD10, that the 
presence of PAbs was associated with concomitant PSC and also with faster disease progression in patients with 
CD. Interestingly, anti-GP2 and anti-CUZD1 antibodies predicted different features of disease progression and 
notably, only IgA but not IgG antibodies were related to the development of complications. In addition, various 
other target specific auto- and anti-microbial IgA antibodies were associated with pathologic bacterial transloca-
tion in cirrhosis, and thus the development complications11,12. The gut-associated lymphoid tissue (GALT) plays 
a central role in the IgA antibody formation. Occurrence of serological antibodies directed against gut innate 
immune proteins or intestinal microorganisms could be a clue of an excessive mucosal immune response due 
to extended microbial challenge or dysregulation. Association between serological antibodies linked to enteric 
bacteria and the progressive disease course in PSC is a reasonable hypothesis13,14.
IgA is an important humoral component of intestinal mucosal immunity. During transportation of the mol-
ecule through the epithelial cell to the mucosal surface, a cleaved fragment of the polymeric IgA receptor (secre-
tory component, SC) remains covalently attached to the dimeric IgA molecule and this complex is referred to 
as secretory IgA (sIgA). The molecule has a dual function. It plays a role in neutralizing microbial antigens and 
in preventing interaction with the intestinal epithelium, a mechanism called immune exclusion. Secretory IgA 
is also involved in the retro-transportation of antigens to GALT that has important immunological functions15. 
After retro-transportation of sIgA molecules, they reach the systemic circulation via the thoracic duct and thus 
can be detectable in sera. In healthy individuals, however, the percentage of SC containing IgA in terms of the 
total IgA pool is less than 1%.
The aims of this study were to investigate1: the prevalence and type of target specific PAbs in a mixed cohort 
of pediatric and adult PSC patients with and without IBD2; the association between PAbs and both clinical and 
laboratory characteristics of the disease3; whether the presence of PAbs is associated with a progressive disease 
course in PSC; and4 the possible mechanisms related to the formation of PSC-associated PAbs.
Results
Frequency of target-specific PAbs in PSC. Frequencies of IgA and IgG isotype PAbs in PSC and various 
control groups comprising healthy blood-donors and both IBD and CLD patients are summarized in Table 1. A 
total of 46.2% (30/65) of PSC patients were positive for either one of the two target-specific PAbs (anti-CUZD1 
and anti-GP2), with a significant difference compared to healthy controls (0.0%, P < 0.001) and all disease control 
groups (CD: 26.8%, P < 0.001 and UC: 7.6%, P < 0.001 or aLC: 6.7%, chrHCV: 4.2% and PBC: 4.9%, P < 0.001 
for all CLD). Distribution of the two types of PAbs in PSC was equal, 30.8% (20/65) for each. One-third of the 
positive cases (10/30) showed double positivity (anti-CUZD1 and anti-GP2). Anti-GP2 antibody positivity was 
exclusively IgA isotype, while anti-CUZD1 antibodies were of both IgA and IgG isotypes.
Association between target-specific PAbs and clinical or laboratory characteristics of PSC. We 
analyzed clinical and laboratory characteristics of PSC patients according to their PAb status and summarized 
these results in Table 2.
PAbs demonstrated no association with gender and younger age at diagnosis. Several laboratory and clinical 
parameters, indicating more severe disease were significantly higher in the presence of anti-GP2 IgA antibody. 
Patients with anti-GP2 IgA antibodies had a significantly shorter disease duration (4 [2–7] vs. 7 [3–10] years, 
P = 0.009), and increased Mayo risk score. All liver enzymes were significantly elevated, while albumin level was 
decreased in anti-GP2 IgA positive cases compared to anti-GP2 negative ones. There was an elevated occurrence 
PSC 
(N = 65)
Inflammatory bowel disease (N = 427) Healthy control Chronic liver diseases (N = 488)
CD (N = 257) UC (N = 170) HC (N = 100) aLC (N = 267) chr HCV (N = 119) PBC (N = 102)
% n % n p-value % n p-value % n p-value % n p-value % n p-value % n p-value
Anti-GP2 IgA 30.8 20 6.2 16 <0.001 0 0 <0.001 0 0 <0.001 4.9 13 <0.001 4.2 5 <0.001 3.9 4 <0.001
Anti-GP2 IgG 0 0 7 18 0.030 0 0 x 0 0 x 0 0 x 0 0 x 0 0 x
Anti-CUZD1 IgA 18.5 12 12.1 31 0.175 4.7 8 0.001 0 0 <0.001 1.9 5 <0.001 0 0 <0.001 1 1 <0.001
Anti-CUZD1 IgG 20 13 16.3 42 0.484 5.9 10 0.001 0 0 <0.001 0.4 1 <0.001 0 0 <0.001 0 0 <0.001
Anti-CUZD1 (IgA 
or IgG) 30.8 20 21 54 0.095 7.6 13 <0.001 0 0 <0.001 2.2 6 <0.001 0 0 <0.001 1 1 <0.001
Anti-CUZD1 and 
Anti-GP2 15.4 10 3.5 9 <0.001 0 0 <0.001 0 0 <0.001 0 0 <0.001 0 0 <0.001 0 0 <0.001
Anti-CUZD1 or 
Anti-GP2 46.2 30 26.8 69 <0.001 7.6 13 <0.001 0 0 <0.001 6.7 18 <0.001 4.2 5 <0.001 4.9 5 <0.001
Table 1. Target-specific anti-pancreatic antibodies (PAbs) in patients with primary sclerosing cholangitis 
(PSC) and various healthy and diseases control groups. CD: Crohn’s disease, UC: ulcerative colitis, HC: 
healthy controls, aLC: alcoholic liver cirrhosis, chr HCV: chronic hepatitis C virus, PBC: primary biliary 
cholangiopathy, PSC: primary sclerosing cholangitis. PAbs: pancreatic autoantibodies, GP2: glycoprotein 2, 
CUZD1: CUB and zona pellucida-like domain 1. p-values pertain to comparisons between PSC and the given 
control group, x: non applicable.
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of cirrhosis in anti-GP2 IgA-positive patients (35% vs. 11.1%, P = 0.022). CUZD1 IgA-positivity was associated 
with shorter disease duration and higher ALP, while CUZD1 IgG-positivity with lower albumin level. There was 
no difference in Mayo risk score according to anti-CUZD1 antibody status. The presence and subtype of concom-
itant IBD were similar according to PAb status.
Significance of target-specific PAbs in the risk of progressive disease course in PSC. Seven 
patients underwent prior orthotopic liver transplantation (OLTx) during the follow-up period. In all cases the 
indication was the development of end-stage liver disease. Six patients died due to liver-related complications, 
three out of six deaths occurred after OLTx, therefore the composite end-point (OLTx and/or liver-related death) 
occurred in a total of 10 patients. One patient died due to acute myocardial infarction, this case was censored 
at time of event. Median follow-up from inclusion was 2632 [IQR: 286–3022] days. Development of colon can-
cer occurred in 2, while biliary tract cancer in 1 patient. Nine of involved patients had at least one episode of 
cholangitis.
We analyzed the association of clinical variables and the different PAbs with poor disease outcome. In 
Kaplan-Meier analysis, the median time to OLTx and/or liver-related death was 490 days (IQR: 49–1033). 
Mayo risk score and the presence of cirrhosis (PLog-rank < 0.001 and =0.007, respectively), but not gender 
(PLog-rank = 0.441), age at onset (PLog-rank = 0.884), disease location (PLog-rank = 0.722) or concomitant IBD 
(PLog-rank = 0.432) were significantly associated with faster disease progression (Supplementary Figure 1 and 
Supplementary Table 1).
Positivity for IgA isotype anti-GP2 antibody (PLog-rank = 0.008), but not for IgA or IgG isotype anti-CUZD1 
antibodies (PLog-rank = 0.335 and 0.998, respectively) predicted OLTx and/or liver-related death, see Fig. 1. 
Accordingly, univariate Cox regression analysis (Supplementary Table 1) revealed anti-GP2 IgA-positivity as a 
predictor for poor disease outcome (HR: 5.15 [1.33–19.97], P = 0.018), that remained an independent predictor 
after adjusting for Mayo risk score in multivariate Cox-regression analysis (HR: 4.69 [1.05–21.04], P = 0.043). A 
similar tendency was found when we adjusted for the presence of cirrhosis, instead of Mayo risk score (HR: 3.74 
[0.9–15.55], P = 0.07). In sensitivity analysis, positivity for anti-GP2 IgA was associated with poor outcome in the 
subgroup of patients with adult onset PSC (PLog-rank = 0.034) and concomitant IBD (PLog-rank < 0.001), but not in 
the subgroup of patients with pediatric onset PSC (PLog-rank = 0.098) and no concomitant IBD (PLog-rank = 0.666).
Significance of classic serological markers in the risk of progressive disease course in PSC. We 
also determined the frequency of classic serological markers in our PSC cohort. A total of 83.1% (54/65) and 
28.1% (18/64) of PSC patients were positive for IgA/IgG atypical P-ANCA and ASCA and significantly different 
from the healthy controls (4%, P < 0.001 and 16%, P = 0.04). Regarding Ig isotypes, atypical P-ANCA was pri-
marily IgG, while ASCA was equally IgG or IgA: 83.1% vs. 40% and 18.8% vs. 21.9%, respectively. Furthermore, 
18.8% and 9.4% of the patients were positive for IgA type anti-OMP PlusTM and EndoCab antibody, respectively. 
However, the frequency of these latter serological antibodies did not differ from those of healthy controls (20% 
and 4.7%).
Association of these antibodies with poor disease outcome was also assessed in Kaplan-Meier analysis. Neither 
IgG nor IgA isotypes of these serological antibodies were associated with the risk of the progressive disease course 
nor were corresponding IgA isotypes, see Fig. 2.
Anti-GP2 IgA
p-value
Anti-CUZD1 IgA
p-value
Anti-CUZD1 IgG
p-valueNegative (n = 45) Positive (n = 20) Negative (n = 53) Positive (n = 12) Negative (n = 52) Positive (n = 13)
Male gender 68.9% (31) 75% (15) 0.617 71.7% (38) 66.7% (8) 0.729 71.2% (37) 69.2% (9) 0.892
Presence of cirrhosis 11.1% (5) 35% (7) 0.022 15.1% (8) 33.3% (4) 0.141 21.2% (11) 7.7% (1) 0.263
Presence of IBD 77.6% (38) 70% (14) 0.638 73.6% (39) 75% (9) 0.92 69.2% (36) 92.3% (12) 0.09
Ulcerative Colitis 46.9% (23) 60% (12)
0.138
43.4% (23) 66.7% (8)
0.234
44.2% (23) 61.5% (8)
0.234
Crohn’s Disease 30.6% (15) 10% (2) 30.2% (16) 8.3% (1) 25% (13) 30.8% (4)
Age at diagnosis (yr) 23 (17–37) 23.5 (18–33) 0.764 25 (18–37) 18 (15–27) 0.098 25 (17–37) 19 (16–27) 0.118
Disease duration (yr) 7 (3–10) 4 (2–7) 0.027 6 (4–10) 2 (1–5) 0.002 6 (3–10) 3.5 (2–6.5) 0.183
Albumin (g/L) 45 (42–47) 40 (39–43) 0.001 44 (40–47) 40 (37–43) 0.116 44 (40–47) 40 (37–41) 0.019
Bilirubin (μmol/L) 15 (11–20) 17 (11–34) 0.383 15 (10–21) 17 (12–37) 0.188 15 (11–22) 20 (15–24) 0.355
AST (U/L) 32 (25–43) 69 (50–96) <0.001 37 (28–61) 51 (36–80) 0.168 42 (28–70) 41 (36–56) 0.672
ALT (U/L) 38 (21–64) 90 (56–165) 0.002 47 (24–100) 85 (40–165) 0.207 50 (27–104) 64 (40–100) 0.670
GGT(U/L) 97 (44–208) 298 (141–499) 0.001 147 (63–310) 193 (60–478) 0.430 160 (82–332) 142 (53–305) 0.758
ALP (U/L) 420 (246–595) 898 (637–1532) <0.001 516 (326–688) 902 (260–1800) 0.030 552 (367–765) 901 (260–1068) 0.653
Mayo risk score −0.859 (−1.447–0.131)
−0.072 
(−0.6–0.658) 0.010
−0.6  
(−1.378–0.174)
−0.321 
(−0.834–0.292) 0.369
−0.579 
(−1.286–0.203)
−0.564 
(−0.775–0.073) 0.636
Table 2. Associations between different target-specific anti-pancreatic antibodies (PAbs) and clinical or 
laboratory characteristics of primary sclerosing cholangitis (PSC) at enrolment. Variables are summarized as: 
percentage, (n) or median (25–75 percentile values). ALP: alkaline phosphatase, ALT: alanine transaminase, 
AST: aspartate transaminase, CUZD1: CUB and zona pellucida-like domains 1, GGT: gamma glutamyl 
transferase, GP2: glycoprotein 2, PAbs: pancreatic autoantibodies, IQR: inter-quartile range Significant 
associations are indicated in bold.
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Anti-GP2 IgA antibody status is associated with increased secretory IgA concentration. Serum 
levels of total sIgA were significantly higher in patients with PSC compared to healthy controls (median [IQR], 
96 [73–180] vs. 30 [21–42] μg/ml, P < 0.001). Furthermore, anti-GP2 IgA positive cases had higher sIgA levels 
compared to anti-GP2 IgA negative ones (149 [86–246] vs. 89 [71–118] μg/ml, P = 0.021). No difference in serum 
sIgA levels were observed in case of other serological antibodies (Table 3).
Characterization of GP2 antibodies. Finally, we characterized anti-GP2 IgA antibodies in patients with 
PSC and Crohn’s disease in a flow-cytometry subtyping assay. The presence of secretory component (SC) on 
GP2 IgA antibodies was 68.4% in PSC (13/19) similar to the frequency (75%,9/12) observed in patients with CD 
without PSC, see Fig. 3.
Discussion
Previously, we observed high frequency of PSC in anti-GP2-positive CD patients10. We, as well as others16 also 
reported associations of novel target-specific PAbs (anti-GP2 and anti-CUZD1) with various aspects of progres-
sive disease course in CD patients. Interestingly only IgA, but not IgG isotype antibodies were related to the 
development of complications in that prospective, large-scale study10. Therefore, we aimed to investigate the 
prevalence and clinical importance of different target-specific PAbs in a prospective PSC cohort with respect to 
different immunoglobulin isotypes.
Simultaneously with a research group from Germany, we demonstrated enhanced IgA type anti-GP2 antibody 
formation in PSC17,18. We used the same cell-based IIF test with an identical cut-off value. As shown elsewhere, 
Figure 1. Progressive disease course in primary sclerosing cholangitis (PSC) according to the presence of 
different target-specific anti-pancreatic antibodies. Patients positive for anti-GP2 IgA have higher cumulative 
probability of disease progression defined by need for OLTx and/ or death compared to those negative for 
anti-GP2 IgA antibody. (A) Neither anti-CUZD1 IgA and nor anti-CUZD1 IgG were associated with the 
progressive disease course (B) GP2: glycoprotein 2, CUZD1: CUB and zona pellucida-like domain-containing 
protein 1.
www.nature.com/scientificreports/
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IIF test appears to detect anti-GP2 IgA in patients with PSC better in contrast to ELISA10. The IIF test used in 
this study detects the interaction of IgA with glycosylphosphatidylinositol (GPI)-anchored GP2 on the surface of 
HEK239 cells6. This might provide a unique epitope structure of GP2 which could be different from one of GP2 
adsorbed to ELISA solid phases. A careful comparison with the findings of Jendrek et al. published as a full paper 
recently19 revealed however, some differences. In our PSC patient cohort, occurrence of anti-GP2 IgA was lower 
(30.8% vs. 48.7%), while that of anti-CUZD1 antibodies was higher (IgA: 18.5% vs. 9.4% and IgG: 20% vs. 6.3%). 
Figure 2. Progressive disease course in primary sclerosing cholangitis (PSC) according to the presence of 
various classic serological markers. Neither IgA and nor IgG atypical P-ANCA (A) ASCA (B) anti-OMP (C) and 
EndoCab antibodies (D) were associated with the progression of disease. ASCA: anti-Saccharomyces cerevisiae 
antibodies, P-ANCA: perinuclear anti-neutrophil cytoplasmic antibody, EndoCab: endotoxin-core antibody.
www.nature.com/scientificreports/
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The reason for these differences is not fully understood, but is most probably attributed to the composition of the 
patient populations. First, the Mayo risk score reflecting disease severity was higher in their cohort. Second, the 
occurrence of biliary tract cancer was 12.3%, while none of our patients had CCA at baseline. Third, in that study 
anti-GP2 IgA positivity was not exclusively associated with PSC, but rather with the presence of large bile duct 
diseases, irrespectively of their malignant or benign character based on findings in their disease control groups. 
Finally, in our study, we used an extensive CLD group with various etiology as disease controls in contrast to the 
study of Jendrek et al. Neither patients with small bile duct disease (primary biliary cholangitis, PBC n = 102), nor 
patients with alcoholic liver cirrhosis showed increased PAb frequency. This later finding is particularly intrigu-
ing, because in cirrhosis we found high frequency of various serological antibodies, mainly of IgA isotype, such 
as ASCA (38.5%) or ANCA (52.2%)11,12 that are also frequent in PSC.
Exploring patient characteristics at enrolment, the presence of anti-GP2 IgA-positivity was associated with a 
more severe disease phenotype. Consistently, anti-GP2 IgA predicted faster disease progression during follow-up, 
even after adjusting for the Mayo risk score or the presence of cirrhosis. In our study, both liver-related death and 
OLTx were considered as equal endpoints, since they represent the development of end-stage liver disease as the 
result of the progressive fibrosis. In the parallel study of Jendrek et al., anti-GP2 IgA-positivity also identified a 
subgroup of patients with high mortality. Notably, poor survival was primarily attributed to cholangiocarcinoma 
(CCA) and not to the development of end-stage liver disease in their cohort. In our cohort, only 1 patient (1.5%) 
developed biliary tract cancer during follow-up, therefore evaluation of PAbs regarding the development of CCA 
was not possible. This CCA rate is lower than the reported 8–13.2% in other studies20,21, but equals with those 
ones from Israel (2.1%) and the Netherlands with corresponding follow-up times in recent reports22,23. Supporting 
clinical evidence for the anti-GP2 IgA - fibrosis linkage in PSC might be the observation that anti-GP2 IgA was 
more prevalent in CD patients with stricturing disease in previous reports10,16,24.
Serum level of secretory IgA 
(median (IQR), mg/L)
p-valuenegative positive
ANTIBODIES
Anti-GP2 IgA 89 (71–118) 149 (86–246) 0.021
Anti-CUZD1 IgA 93 (71–160) 149 (85–293) 0.108
Anti-CUZD1 IgG 95 (74–187) 97 (60–126) 0.376
Atypical P-ANCA IgA 100 (71–183) 89 (74–143) 0.810
Atypical P-ANCA IgG 100 (71–115) 95 (74–185) 0.7
ASCA IgA 98 (74–185) 91 (71–143) 0.782
ASCA IgG 96 (73–181) 99 (72–217) 0.783
Anti-OMP Plus IgA 95 (71–176) 111 (77–196) 0.449
EndoCab IgA 94 (73–183) 130 (71–156) 0.836
Table 3. Serum level of total secretory (s)IgA (mg/L) according to the different serologic antibody statuses. 
ASCA: anti-Saccharomyces cerevisae antibody, CUZD1: CUB and zona pellucida-like domains 1, EndoCab: 
endotoxin core antibody, GP2: glycoprotein 2, P-ANCA: perinuclear anti-neutrophil cytoplasmic antibody, 
IQR: inter-quartile range Significant associations are indicated in bold.
Figure 3. Presence of secretory component on GP2 IgA antibodies. Cut-off positivity (0.101) was defined by 
the mean + 2 SD median MFI value of the negative control group (healthy subjects).
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Formation of anti-GP2 antibody represents the breakdown of tolerance towards the GP2 protein. Glycoprotein 
2, an innate immunity protein released from the exocrine pancreas into the intestinal lumen, is also expressed 
on the apical membrane surface of M-cells. There GP2 can interact with FimH-positive bacteria bearing type-1 
fimbriated pyli. GP2-mediated transcytosis is necessary for the initiation of antigen-specific mucosal immune 
responses against this type of bacterial antigen25. Interestingly we showed, that there is an enhanced immunologi-
cal response to a wide range of other enteric bacterial antigens in PSC as well. These were as follows: phosphopep-
tidomannan (ASCA), different endotoxins (EndoCab) and multiple Gram-negative and Gram-positive proteins 
(OMP). In autoimmune liver disorders, atypical P-ANCA was reported to be directed against human β-tubulin 
isotype-5 (TTB-5), a protein which shares an extraordinary high structural homology with the microbial cell 
division protein (FtsZ). FtsZ is present in almost all bacteria in the intestinal microflora. Therefore, occurrence 
of P-ANCA has been considered a sign of immunological response to enteric bacteria13. However, in our study, 
serological response to these bacterial antigens was not associated with disease progression in PSC.
To explore the possible link between mucosal immunity and the development of severe phenotype in PSC, the 
serum levels of total sIgA were measured. A novel finding of our study is that in PSC, the total sIgA levels were 
significantly elevated, namely three-fold higher, compared to healthy controls. These results indicate an elevated 
retro-transport of sIgA from the gut mucosal surface in PSC. An additional two-fold elevation of total sIgA levels 
were found in anti-GP2 IgA-positive cases that was not seen in the presence of other serological anti-microbial 
antibodies or ANCA. These results suggest that retro-transport is specifically further enhanced in patients with 
anti-GP2 IgA-positivity. Flow-cytometry based characterisation of anti-GP2 IgA-positive samples revealed that 
SC was present on these molecules in up to 68.4% of cases. This high percentage of SC strongly indicates that 
after secretion to the gut lumen, anti-GP2 IgA antibodies are also retro-transported across the mucosal epithe-
lium. Retro-transported sIgA molecules, however, are not “lonely” particles, but rather exist in partnership with 
their antigens. Since antigen-coupled sIgA molecules are those that have high affinity to their epithelial recep-
tors26, anti-GP2 IgA antibodies grab GP2-coated FimH-positive bacteria as companions. In this way enhanced 
retro-transport of anti-GP2 IgA might increase microbial overload in the mucosal compartment and perpetuate 
antigen-induced signalling. Memory T lymphocytes primed in the inflamed gut and homing to the biliary tract 
via aberrantly expressed adhesion molecules plays a fundamental role in the extension of gut inflammation to 
the biliary tract27. Interestingly, FimH has been recently identified as a ligand of Toll-like receptor (TLR)-428. 
Sustained TLR4 activation leads to enhanced fibrosis through TGF-beta signaling29. At the same time, FimH 
elicits an immune response with enhanced type I Interferon production that has been linked to disease ampli-
fication in autoimmunity30. These mechanisms could serve an explanation of how the breakdown of tolerance 
towards GP2 in the gut is associated with the development of enhanced fibrosis, and thus disease progression in 
the liver. The GP2—FimH axis deserves further exploration in the pathogenesis of PSC and might also be a highly 
intriguing issue from the therapeutic point of view. GP2 has a high structural and functional homology with 
uromodulin (Tamm-Horsfall protein in the urinary tract)9. Recombinant vaccine against the adhesion protein of 
FimH is already under development in recurrent urinary tract infections. Furthermore mannose-derived FimH 
antagonists, also hold promise as a novel treatment for UTIs and Crohn’s disease31–33.
In summary, the presence of target-specific PAbs is associated with PSC and its more severe phenotype, but 
not with other CLDs including cholestatic liver disease with small bile duct involvement. The findings of our 
prospective referral cohort study indicate that anti-GP2 IgA may be a useful additional serological tool in the 
stratification of PSC patients and is associated with the progressive disease course. In addition, occurrence of IgA 
type anti-GP2 antibody may serve as an additional clue towards the significance of gut-liver interactions in the 
disease course of PSC.
Methods
Patient population. We performed an observational cohort study among adult and pediatric PSC patients 
recruited in Hungarian referral hepatology centers (Hungarian Autoimmune Liver Disease Study Group). This 
study population is equal with the patient cohort published previously34, with exception that 4 patients were 
excluded due to prior liver transplantation in this study. In total 65 well-characterized PSC patients with a com-
plete clinical follow-up (adult: 55 [male/female: 39/16], median age at presentation: 28 years [IQR: 19–37], 
median disease duration: 6 years [2–10] and children: 10 [male/female: 7/3], median age at presentation: 10 years 
[IQR: 6–11], disease duration: 5 [1.5–7.5]) were included between January, 2006 and December, 2007. Clinical 
characteristics of patients at enrolment are presented in Table 4.
Diagnosis of PSC was based on clinical, biochemical, serological and cholangiographic (magnetic resonance 
or endoscopic imaging) features or, when indicated, on histological findings35. Patients with any concomitant 
malignant disease were excluded. Blood samples and detailed description of clinical phenotypes were obtained 
at inclusion. Clinical data were determined by thorough review of patients’ medical records, which had been 
collected in a uniform format. Medical records that documented disease phenotype (age at onset of disease, dura-
tion [time elapsed from diagnosis until study inclusion], type of PSC – large duct or small duct), presence and 
type of concomitant IBD, presence of overlap syndrome, presence of cirrhosis and portal hypertension related 
complications (e.g. ascites, encephalopathy, oesophageal varices or variceal bleeding), prior orthotopic liver trans-
plantation (OLTx), co-morbidities and medication (e.g. ursodeoxycholic acid, steroid, immunosuppressive and/
or biological therapy) at inclusion were retrospectively analyzed for the period prior to the prospective follow-up. 
At enrolment, revised Mayo risk score was calculated2 and biochemical analyses were performed using standard 
routine laboratory protocols for tests including platelet count, creatinine, total bilirubin, albumin, international 
normalized ratio (INR) of prothrombin time, aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase (ALP), and γ-glutamyl-transferase (GGT).
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Phenotypical characterization of PSC patients during prospective follow-up. Phenotypical char-
acterization of this patient cohort was performed previously and is provided similarly as the publication34. PSC 
patients were enrolled into a prospective follow-up study, where treating physicians registered laboratory data, 
imaging and endoscopic findings, medical treatment, date and type of complications (cirrhosis, colorectal cancer, 
biliary tract cancer: cholangiocarcinoma [CCA] gallbladder cancer [GBC] or cholangitis) during regular outpa-
tient follow-up visits and inpatient stays. In Hungary, a follow-up visit is usually scheduled for every 6 months at 
a specialized hepatology center (the actual interval varies between 3–6 months). Collected data were transferred 
and stored in a database for analysis. On December 1st 2015, all patients’ charts and data were reviewed and 
updated for the data points mentioned above. Adverse outcome was defined as need for OLTx and/or liver-related 
death (composite end-point). Follow-up for a particular patient was terminated if adverse outcome occurred or 
there was no further record available. One case with a non-liver related death (myocardial infarction) was cen-
sored at the time of event.
Control groups. Healthy controls and two disease control groups (patients with inflammatory bowel diseases 
[IBD] and chronic liver diseases [CLD]) were included.
The healthy control group consisted of 100 age-matched individuals (male/female: 45/55, age: 30 years [21–
40]) selected from consecutive blood donors in Debrecen. Control subjects did not have any known gastrointes-
tinal or liver diseases.
The inflammatory bowel disease control group consisted of a previously reported patient cohort (CD: 257, 
male/female: 108/148, age: 25 [19–33] years and ulcerative colitis [UC]: 170, male/female: 78/92, age: 34 [23–44] 
years)10.
The chronic liver disease control group consisted of patients with primary biliary cholangitis without cirrho-
sis (PBC, n = 102, male/female: 4/98, age: 59 [52–66] years), chronic hepatitis C virus (chrHCV, n = 119, male/
female: 50/69, age: 55 [47–65] years) and alcoholic liver cirrhosis (aLC, n = 267, male/female: 147/120, age: 58 
[51–66] years). The diagnosis of PBC was based on biochemical evidence of cholestasis, serum anti-mitochondrial 
antibodies (AMA) and/or PBC-specific AMA-M2 positivity, compatible histology, and the exclusion of extrahe-
patic cholestasis36. The diagnosis of chronic HCV was based on positive HCV ribonucleic acid, elevated liver 
function tests (2xULN for more than 6 months) and compatible liver biopsy, if available. The diagnosis of cirrho-
sis was based on clinical, biochemical, imaging, and, when available, histological data.
Serological Analysis. Blood samples were obtained at enrolment from each patient and were frozen at 
−70 °C until testing. All serological assays were performed in a blinded fashion without prior knowledge of the 
patient’s clinical information.
Patients with PSC (n = 65)
Median (IQR)
Age at diagnosis (years) 23 (17–37)
Disease duration (years) 6 (2–8)
Albumin (g/L) 43 (40–46)
Bilirubin (µmol/L) 15 (11–23)
ALT (U/L) 52 (32–100)
AST (U/L) 42 (28–69)
GGT (U/L) 154 (63–320)
ALP (U/L) 566 (326–822)
INR 1.0 (1.0–1.2)
Platelet (109/L) 257 (187–321)
Mayo risk score −0.564 (−1.142–0.174)
% (n)
Children 15.4% (10)
Male 70.8% (46)
Cirrhosis 20.3% (14)
IBD 73.9% (48)
Crohn’s Disease 35.4% (17)
Ulcerative Colitis 64.6% (35)
Overlap syndrome 13.8% (9)
Small duct PSC 7.7% (5)
Table 4. Clinical and laboratory characteristics of patients with primary sclerosing cholangitis (PSC). ALP: 
alkaline phosphatase, ALT: alanine transaminase, AST: aspartate transaminase, GGT: gamma glutamyl 
transferase, INR: international normalized ratio, IBD: inflammatory bowel disease, IQR: inter-quartile range 
The entire cohort comprised 69 patients but those with prior liver transplantation (n =  4) were excluded from 
the study.
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Detection of target specific serological antibodies. Autoantibodies. IgA and IgG type anti-GP2 and 
anti-CUZD1 antibodies as well as atypical perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) were 
detected in sera using commercially available cell-based IIFT according to the test instructions [CIBD Mosaic, 
EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany]. A specific fluorescence at a dilution of 
1:10 or higher was considered positive for anti-GP2 and anti-CUZD1, while 1:32 or higher for atypical P-ANCA 
as recommended by the manufacturer. Detailed description of the protocols has been reported previously10,12 and 
given in the Supporting Material.
Anti-microbial antibodies. Anti-Saccharomyces cerevisiae (ASCA) (IgA and IgG, US FDA-cleared) and anti-OMP 
Plus (IgA) (research use only) antibodies were detected by commercially available sandwich enzyme-linked 
immunosorbent assays (ELISA) employing a specially purified preparation of Saccharomyces cerevisiae antigen 
and a mixture of multiple bacterial proteins derived from two species of intestinal bacteria (one Gram-positive 
and one Gram-negative) respectively, with a cut-off positivity at 25 U for all (QUANTA Lite®, Inova Diagnostics, 
San Diego, CA) as recommended by the manufacturer. Endotoxin core IgA antibody (EndoCAb) directed against 
a mixture of incomplete endotoxins of 4 different species (Pseudomonas aeruginosa, Salmonella typhimurium, 
Escherichia coli and Klebsiella aerogenes) was detected by commercially available ELISA (Hycult Biotechnology, 
Uden, Netherlands). The cut-off positivity was 195 AU/mL, defined as values exceeding the 95th percentile level 
of the healthy control group.
Detection of serological antibody of mucosal origin. Secretory subtype of total IgA (sIgA) was 
detected by an in-house sandwich ELISA in PSC and healthy controls. Detailed description of this experiment is 
presented in the Supporting Material.
Characterization of IgA type anti-GP2 antibodies. We used GP2-coated bead-based in-house flow 
cytometric immunoassay to determine the presence of secretory component (SC) on anti-GP2 IgA antibodies in 
sera. Detailed description of this experiment is presented in the Supporting Material.
The IgA subtype analysis was performed in anti-GP2 IgA-positive sera of PSC (n = 19) and Crohn’s disease 
patients without PSC (n = 14) by IIFT and was also verified by ELISA test (anti-GP2 IgA, GA Generic Assays, 
Dahlewitz/Berlin, Germany). Anti-GP2 IgA-negative sera of healthy subjects (n = 20) served as controls.
Ethical considerations. The study protocol was approved by the Regional and Institutional Research 
Ethics Committee of University of Debrecen and the National Scientific and Research Ethics Committee 
(DEOEC-RKEB/IKEB 5306–9/2011, 3515–2011, 3885/2012/EKU [60/PI/2012], 3880/2012/EKU [59/PI/2012]). 
Each patient was informed of the nature of the study and gave informed consent in writing. All methods were 
performed in accordance with the relevant guidelines and regulations2,6,35–37.
Data availability statement. The datasets generated and analyzed during the current study are available 
from the corresponding author on reasonable request.
Statistical methods. Variables were tested for normality using Shapiro Wilk’s W test. Continuous variables 
were summarized as medians (interquartile range [IQR, lowest 25% - highest 25%]) and were compared with the 
Mann-Whitney U test. Categorical variables were compared with χ2 test or Fisher’s exact test, as appropriate. 
Kaplan–Meier analysis was used to determine association between serological antibodies and adverse disease 
outcome (OLTx and/or liver-related mortality). Differences in observed survival were assessed by the log-rank 
test. The association of categorical clinical variables or serological antibodies with adverse disease outcome dur-
ing the follow-up was evaluated by univariate Cox-regression analysis. Multivariate analyses were performed to 
adjust for the Mayo risk score or presence of cirrhosis with forced entry method. Associations are given as hazard 
ratio [HR] with 95% confidence intervals [CI]. For statistical analysis and graphical presentation, the SPSS v.22.0 
(SPSS, Chicago, IL), and GraphPad Prism 6 (San Diego, CA) programs were used. A two-sided probability value 
of < 0.05 was considered to be statistically significant.
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